American Society of Hematology

Figure 2.

$Incidence of mutation, copy loss, structural variation, or high exon 10–spliced transcript of CRBN correlates with outcome to POM in a LEN-refractory cohort. High exon 10–spliced transcript correlates with outcome to induction therapy in ND myeloma. (A) PFS of those who carried the 4 types of CRBN aberration vs those unaffected in the LEN-refractory cohort exposed to POM-based therapy. (B) PFS of those carrying ≥1 of any type of CRBN aberration vs those unaffected in the LEN-refractory cohort exposed to POM-based therapy. (C) Association of high exon 10–spliced CRBN transcript with PFS in the ND cohort undergoing induction therapy. (D) Overall survival (OS) of those carrying ≥1 of any type of CRBN aberration vs those unaffected in the LEN-refractory cohort exposed to POM-based therapy. (E) Association of high exon 10–spliced CRBN transcript with OS in the ND cohort undergoing induction therapy. Comparison of survival curves by log-rank testing in all cases.$

Incidence of mutation, copy loss, structural variation, or high exon 10–spliced transcript of CRBN correlates with outcome to POM in a LEN-refractory cohort. High exon 10–spliced transcript correlates with outcome to induction therapy in ND myeloma. (A) PFS of those who carried the 4 types of CRBN aberration vs those unaffected in the LEN-refractory cohort exposed to POM-based therapy. (B) PFS of those carrying ≥1 of any type of CRBN aberration vs those unaffected in the LEN-refractory cohort exposed to POM-based therapy. (C) Association of high exon 10–spliced CRBN transcript with PFS in the ND cohort undergoing induction therapy. (D) Overall survival (OS) of those carrying ≥1 of any type of CRBN aberration vs those unaffected in the LEN-refractory cohort exposed to POM-based therapy. (E) Association of high exon 10–spliced CRBN transcript with OS in the ND cohort undergoing induction therapy. Comparison of survival curves by log-rank testing in all cases.

This Feature Is Available To Subscribers Only